Announcement
Panboron BNCT, an oncology healthcare enterprise owned by China Biotech Services Holdings Limited (HKEX:8037), announced that its Hainan hospital now offers cross‑border boron neutron capture therapy (BNCT) to international patients through a dedicated international patient services platform. This marks the first medical institution in China to deliver routine clinical BNCT using an overseas‑approved drug‑and‑device combination under the Boao Lecheng International Medical Tourism Pilot Zone’s urgent clinical‑need policy.
Facility and Regulatory Context
The Panboron (Hainan) BNCT Hospital occupies approximately 14,000 square metres in the Boao Lecheng pilot zone. The facility began trial operations in February 2026, performed its inaugural BNCT treatment on 19 March 2026, and treated its first international patient on 20 May 2026. The centre operates under import approval based on urgent clinical need; the NeuCure BNCT treatment system, NeuCure Dose Engine software, borofalan (¹⁰B) marketed as Steboronine®, and RayStation v2025 have not yet been registered with China’s National Medical Products Administration (NMPA) and are used clinically only at this hospital.
Treatment Process
BNCT combines an intravenous infusion of Steboronine®—the world’s first approved boron drug for BNCT that preferentially accumulates in tumour cells—with irradiation by an epithermal neutron beam. The boron‑10 atoms capture neutrons, releasing high‑energy alpha particles and lithium‑7 nuclei that travel only 5‑10 µm, effectively confining the radiation to the boron‑loaded tumour cells. Under applicable indications, BNCT is typically delivered in a single neutron irradiation session, allowing patients travelling to Hainan to complete treatment in one visit.
International Patient Services
Prior to travel, physicians conduct a remote multidisciplinary review of medical records to confirm BNCT suitability and determine eligibility. During the stay, coordinators provide multilingual medical interpretation and travel support, and a structured follow‑up programme is offered after discharge. According to China’s National Immigration Administration, citizens of 61 countries may enter Hainan visa‑free for up to 30 days for purposes that include medical treatment.
Milestones and Patient Volume
As of October 2026, nearly 60 patients—originating from 20 Chinese provinces and municipalities as well as from overseas—have completed BNCT at the Hainan hospital. The company is also participating in the 9th China International Import Expo in Shanghai (5‑10 November 2026), showcasing its BNCT capabilities.
Disclaimer
The press release is for informational purposes only and does not constitute medical advice, product recommendation, or proof of efficacy. Patients are advised to consult qualified medical institutions for diagnosis and treatment.